- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07300527
Cognitive Behavior Therapy Among Patients With Major Depressive Disorder-Multiple Episodes.
Cognitive Behavior Therapy for Dysfunctional Cognitive and Behavioral Patterns and Functional Outcomes Among Patients With Major Depressive Disorder-Multiples Episodes: Randomized Control Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this experimental study, 120 patients will be screened for eligibility from various government and private hospitals. Participants meeting the DSM-5-TR criteria for Major Depressive Disorder (multiple episodes) will be considered. Eighty eligible participants will be randomly assigned to the experimental group (n = 40) and control group (n = 40). Participants aged 18-50 years will be included. Following approval from the university and formal permissions from hospitals and patients, all ethical guidelines will be strictly observed. Eligible participants will be selected based on the inclusion criteria. The CBT group will receive two sessions per week, gradually reduced over time, with each session lasting 45-60 minutes. Pre- and post-assessments will be conducted using standardized measures to evaluate changes in depression severity and related psychological variables.
Expected outcome: The intervention is expected to significantly reduce symptoms of depression and anxiety among participants. Improvements are anticipated in help-seeking attitudes, motivation toward health behavior change, and overall quality of life. CBT is also expected to enhance meta-memory and meta-cognitive functioning. These outcomes will support the effectiveness of CBT in treating patients with recurrent MDD.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Qasir Abbas Dr, PhD Clinical Psychology
- Phone Number: 10245 923337683133
- Email: qasirabbas47@yahoo.com
Study Contact Backup
- Name: Ayesha Mirza Ms, MS Clinical Psychology
- Phone Number: 1245 923211743095
- Email: drqasirabbas@gcuf.edu.pk
Study Locations
-
-
Punjab Province
-
Faisalabad, Punjab Province, Pakistan, 38000
- Government College University Faisalabad
-
Contact:
- Qasir Abbas
- Phone Number: 03337683133
- Email: qasirabbas47@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age range: 18-50 years No physical, psychiatric, or psychological conditions. patients who meet multiple Episodes. who meet DSM 5 TR Major Depressive Disorder Criteria. patients who meet moderate severity at patient health questionnaire scale .
Exclusion Criteria:
- age range: below 18 and above 50 years. presence of any physical, psychiatric, or psychological conditions. who do not meet DSM 5 TR Major Depressive Disorder Criteria. range at patient health questionnaire scale is mild , minimal or severe or moderately severe.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1st Arm (1- Experimental)
Patients will receive cognitive behavioral Therapy
|
This involves 10 sessions, 2 sessions per week will be conduct, session 1 ( psychoeducation about the problem, second will be cognitive Distortions, thirdly, automatic Thoughts , ABC Worksheet (Antecedent-Belief-Consequence), (Greenberger & Padesky, 2016) Daily Thought Monitoring Sheet, "Catch It - Check It - Change It" model. fourthly, Core beliefs And Dysfunctional Schemas, Downward Arrow Technique (Beck, 2011) Flashcards for Positive Beliefs, "What does that say about me?" , REFRAMING (Beck, 2011), fifth, Behavioral Activation, Increase engagement in pleasurable and meaningful activities. sixth, Memory and concentration, Enhance mindfulness and address cognitive memory concerns. To help patient focus on present moment. seventh, stress management Training, eighthly, problem solving skills, Relationship management skills, lastly, relapse Prevention, review skills, plan for future, reinforce independence. each session have specific goals and outcomes.
Participants in this arm will receive Treatment as Usual (TAU) provided by the hospital, which may include routine psychiatric care, medication management, and supportive counseling as prescribed by the treating psychiatrist.
No structured psychotherapy sessions, such as CBT, will be administered during the study period.
This group will serve as the control condition to compare the effects of Cognitive Behavioral Therapy (CBT) on depressive symptoms and related psychological outcomes.
Standard care procedures will continue throughout the study, and participants will be assessed at the same pre- and post-intervention time points as the experimental group.
|
|
Active Comparator: 2nd Arm (Waitlist Control Condition)
This group will receive treatment as usual
|
Participants in this arm will receive Treatment as Usual (TAU) provided by the hospital, which may include routine psychiatric care, medication management, and supportive counseling as prescribed by the treating psychiatrist.
No structured psychotherapy sessions, such as CBT, will be administered during the study period.
This group will serve as the control condition to compare the effects of Cognitive Behavioral Therapy (CBT) on depressive symptoms and related psychological outcomes.
Standard care procedures will continue throughout the study, and participants will be assessed at the same pre- and post-intervention time points as the experimental group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Health Questionnaire PHQ-9 (Kroenke, and colleagues, 1999)
Time Frame: at pre-Assessment, after 5 weeks at post-Assessment
|
Kroenke, and colleagues (1999) from Columbia University developed Patient Health Questionnaire.
In the current study Patient Health Questionnaire 9 item questionnaire translated by (Ahmad, Hussain, Akhtar & Shah, 2018).
Each item could be responded to using a 4-point Not at all = 0; several days = 1; More than half the days = 2; nearly every day = 3.
The PHQ-9 has 9 items, each of which is scored 0,1,2,3, leading to a maximum score of 27.
The total scores of 5, 10, 15 and 20 are taken as mild, moderate, moderately severe and severe in terms of the questioner's depressive illness.
Cronbach's alpha for PHQ-9 was 0.91.
The reliability was further supported by split-half reliability for PHQ-9; part 1 (r = 0.86), part 2 (r = 0.84) and correlation between two halves (r = 0.77), Spearman Brown coefficient was 0.87, and Guttmann split-half coefficient was 0.8.
|
at pre-Assessment, after 5 weeks at post-Assessment
|
|
Generalized Anxiety Disorder 7-item scale (GAD-7)
Time Frame: at Pre-Assessment, after 5 weeks at post-Assessment
|
The Generalized Anxiety Disorder 7-item scale (GAD-7) is a widely used self-report screening tool designed to assess the severity of generalized anxiety symptoms.
Developed by Spitzer et al. (2006), the scale consists of 7 items, each rated on a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 21.
Higher scores indicate greater levels of anxiety.
The GAD-7 has demonstrated high internal consistency, with a Cronbach's alpha of 0.92, and test-retest reliability of 0.83, making it a reliable instrument for both clinical and research use.
In the present study, the GAD-7 will be used to measure anxiety symptoms before and after the intervention, allowing evaluation of the impact of Adapted CBT on comorbid anxiety in patients with Major Depressive Disorder.
|
at Pre-Assessment, after 5 weeks at post-Assessment
|
|
WHOQOL BREF Scale (WHO; Skevington, Lotfy &Connell, 2004).
Time Frame: at pre-assessment, after 5 weeks at post-assessment
|
WHO developed WHOQOL BREF scale.
In the current study WHOQOL Brief scale translated by (Ahmad, Hussain, Akhtar & Shah, 2018).
The WHOQOL-Brief, still in field trials, is a subset of 26 items taken from the WHOQOL-100.
The same steps for the scoring WHOQOL-100 should be followed to achieve scores for the Brief.
The four domain scores are scaled in a positive direction with higher scores indicating a higher quality of life.
Three items of the Brief must be reversed before scoring.
|
at pre-assessment, after 5 weeks at post-assessment
|
|
Mental Help-Seeking Attitudes Scale (MHSAS),
Time Frame: at pre-assessment, after 5 weeks at post-assessment
|
The Mental Help-Seeking Attitudes Scale (MHSAS), developed by Hammer, Parent, and Spiker (2018), is a 9-item self-report instrument designed to assess individuals' overall attitudes toward seeking help from mental health professionals.
Each item is rated on a 7-point semantic differential scale (e.g., harmful-beneficial, useless-useful), with higher scores indicating more positive attitudes toward mental health help-seeking.
The MHSAS has demonstrated strong psychometric properties, including high internal consistency with a Cronbach's alpha of approximately .93, and strong test-retest reliability.
The scale has also shown construct validity, being significantly correlated with related variables such as stigma, norms, and intention to seek help.
|
at pre-assessment, after 5 weeks at post-assessment
|
|
Motivation and Attitudes Toward Changing Health (MATCH)
Time Frame: at pre-assessment, after 5 weeks at post-assessment
|
The Motivation and Attitudes Toward Changing Health (MATCH) scale, developed by Hessler et al. (2018) at the Behavioral Diabetes Institute, is a concise 9-item self-report measure designed to evaluate patients' readiness for health-related behavior change.
It includes three subscales: Willingness to Change, Perceived Ability to Change, and Belief that Change is Worthwhile, each containing 3 items.
Responses are rated on a 5-point Likert scale, with some items reverse-scored.
The MATCH scale has shown acceptable internal consistency, with Cronbach's alpha values ranging from 0.61 to 0.74 across subscales, and has demonstrated good construct validity.
|
at pre-assessment, after 5 weeks at post-assessment
|
|
Digit Span Test ( Backward and Forward)
Time Frame: at pre-assessment, after 5 weeks, post-assessment
|
The Digit Span Test, a subtest of the Wechsler Adult Intelligence Scale (WAIS), is used to assess attention, concentration, and working memory.
It includes two components: Digit Span Forward and Digit Span Backward.
In the Forward task, participants repeat a sequence of numbers in the same order as presented, primarily measuring attention span and short-term memory.
In the Backward task, participants repeat the numbers in reverse order, assessing working memory and mental manipulation abilities.
Typically, performance is higher on the forward span than the backward span due to the increased cognitive demands of the latter.
The Digit Span Test has demonstrated adequate internal consistency and reliability, with reported Cronbach's alpha values ranging from .80 to .90, indicating strong psychometric properties for assessing cognitive functioning related to attention and memory.
|
at pre-assessment, after 5 weeks, post-assessment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Qasir Abbas Dr, PhD Clinical Psychology, Government College University Faisalabad
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCUF_PsychThesisTrial
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patients With Major Depressive Disorder
-
Angelini Pharma Česká republika s.r.o.National Institute of Mental Health (NIMH); Institut biostatistiky a analýz... and other collaboratorsTerminatedFirst choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic (FIAT)Adult Patients | Major Depressive Disorder Co-Occurrent With Anxiety | Newly Diagnosed DepressionCzechia
-
Astellas Pharma IncCompletedMajor Depressive Disorder PatientsJapan
-
Astellas Pharma IncCompletedMajor Depressive Disorder PatientsJapan
-
Seaport TherapeuticsPremier ResearchEnrolling by invitationMajor Depressive Disorder (MDD) | Major Depressive Disorder With Anxious DistressUnited States, Czechia, Poland, Bulgaria, Germany, Slovakia
-
SunovionCompletedMajor Depressive Disorder With Mixed FeaturesUnited States, Serbia, Ukraine, Russian Federation, United Kingdom
-
Janssen Research & Development, LLCCompletedMajor Depressive Disorder With Anxious DistressUnited States, Moldova, Republic of, Russian Federation, Ukraine, United Kingdom
-
Novartis PharmaceuticalsTerminatedMajor Depressive Disorder With Suicidal Ideation With IntentTaiwan, Netherlands, Spain, United States, Malaysia, Poland, Canada, Japan, Mexico, Argentina, Turkey (Türkiye), Germany, Brazil, Russia
-
Seaport TherapeuticsPremier ResearchRecruitingMajor Depressive Disorder (MDD) | Major Depressive Disorder With Anxious DistressUnited States, Bulgaria, Czechia, Poland, Slovakia, Germany, Hungary
-
Corporacion Parc TauliHorizon 2020 - European CommissionRecruitingMajor Depressive Disorder (MDD) | Major Depression With Comorbid Anxiety SymptomsSpain
-
Karolinska InstitutetActive, not recruitingDepression - Major Depressive Disorder | Surgery With General AnesthesiaSweden
Clinical Trials on Cognitive Behavior Therapy
-
Laval UniversityUniversity of California, BerkeleyCompleted
-
Center for Psychological ConsultationCompletedObsessive Compulsive DisorderUnited States
-
Stockholm UniversityKarolinska InstitutetCompleted
-
VA Office of Research and DevelopmentCompleted
-
Baylor College of MedicineSouth Central VA Mental Illness Research, Education & Clinical CenterCompletedDepression | AnxietyUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedMajor Depressive DisorderUnited States
-
University of OsloNot yet recruitingCognitive Behavior Therapy | Depression - Major Depressive Disorder | Psychodynamic TherapyNorway
-
Henry M. Jackson Foundation for the Advancement...National Alliance for Research on Schizophrenia and DepressionCompletedSuicide, AttemptedUnited States
-
Shanghai 10th People's HospitalRecruitingColorectal Cancer | Cognitive Behavior Therapy | Immune FunctionChina
-
Neuropsychiatrischen Zentrums Hamburg-AltonaUniversity of Hamburg-EppendorfRecruiting